BUZZ-Marker <a href="https://laohu8.com/S/LENZ">Therapeutics</a> jumps after blood cancer trial data** Shares of drug developer Marker Therapeutics MRKR.O up 29% at $1.63 premarket
** Co reports data from its ongoing early-stage trial testing its experimental therapy, MT-601, in patients with relapsed B-cell lymphoma, a type of blood cancer that has returned after previous treatment
** Co says 66% of patients saw their cancer shrink or disappear, with 50% showing no detectable cancer after treatment
** The therapy had no severe side effects, co says
** As of last close, stock down 60% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments